Average Co-Inventor Count = 6.78
ph-index = 3
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Respivert Limited (9 from 63 patents)
2. Pulmocide Limited (7 from 21 patents)
3. Cancer Research Technology Limited (4 from 262 patents)
4. Topivert Pharma Limited (3 from 26 patents)
20 patents:
1. 11661423 - Heterocyclic compounds as RET kinase inhibitors
2. 11634406 - Inhibitor of p38 MAP kinase
3. 11548896 - Heterocyclic compounds as RET kinase inhibitors
4. 11142515 - Pyrazolyl-ureas as kinase inhibitors
5. 10954241 - Heterocyclic compounds as ret kinase inhibitors
6. 10844067 - Heterocyclic compounds as RET kinase inhibitors
7. 10815217 - Inhibitor of p38 MAP kinase
8. 10626126 - Compounds
9. 10472375 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
10. 10294216 - Pyrazolyl ureas as kinase inhibitors
11. 10273249 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
12. 10189863 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
13. 10160772 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
14. 10045980 - Inhibitor of p38 map kinase
15. 10035810 - 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative